CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Open Label, Multicenter Study of the Safety, Tolerability and Efficacy of Multiple Intravitreal Injections of (Super-dose Anti-VEgf SAVE Trial) 2.0mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01025232
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:20.425513+00:00
Published At: 2017-01-02T00:00:00+00:00
Record Updated At: 2017-01-02
Results Posted At: 2017-01-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Age Related Macular Degeneration", "Choroidal Neovascular Membrane", "Subfoveal Neovascular Age-Related Macular Degeneration", "Macular Degeneration", "Wet Age-Related Macular Degeneration"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-01-02"
protocolSection.identificationModule.nctId: "NCT01025232"
protocolSection.identificationModule.officialTitle: "A Phase I/II Open Label, Multicenter Study of the Safety, Tolerability and Efficacy of Multiple Intravitreal Injections of (Super-dose Anti-VEgf SAVE Trial) 2.0mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-01-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.